Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer

Oncologist

Volumn 16, Issue 8, 2011, Pages 1092-1100

  Miles, David ^a   Roché, Henri ^b   Martin, Miguel ^c   Perren, Timothy J ^d   Cameron, David A ^e   Glaspy, John ^f   Dodwell, David ^g   Parker, Joanne ^h   Mayordomo, José ⁱ   Tres, Alejandro ⁱ   Murray, James Lee ^j   Ibrahim, Nuhad K ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e WESTERN GENERAL HOSPITAL   (United Kingdom)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

^h Biomira Inc   (Canada)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Metastatic breast cancer muc 1 antibody antiestrogen vaccine chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; KEYHOLE LIMPET HEMOCYANIN; MUCIN; PROGESTERONE RECEPTOR; THERATOPE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOMODULATION; INJECTION SITE BURNING; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE STINGING; INJECTION SITE ULCER; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; SEROCONVERSION; SINGLE DRUG DOSE; SUPERFICIAL CANCER; SURVIVAL TIME; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTIBODIES, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; CYCLOPHOSPHAMIDE; DOUBLE-BLIND METHOD; FEMALE; HEMOCYANIN; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MIDDLE AGED; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 80052206741     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0307     Document Type: Article

References (35)

1. Parkins DM. International variation. Oncogene 2004;23:6329-6340.
2. American Cancer Society. Cancer Facts and Figures 2005. Atlanta, GA: American Cancer Society, Inc., 2005;1-60.
3. Ferlay J, Autier P, Boniol M et al. Estimates of cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-592.
4. Sant M, Allemani C, Berrino F et al. Breast carcinoma survival in Europe and the United States. Cancer 2004;100:715-722.
5. Jäger E, Jäger D, Knuth A. Clinical cancer vaccine trials. Curr Opin Immunol 2002;14:178-182.
6. Bitton RJ. Cancer vaccines: A critical review on clinical impact. Curr Opin Mol Ther 2004;6:17-26.
7. Musselli C, Livingston PO, Ragupathi G. Keyhole limpet hemocyanin conjugate vaccines against cancer: The Memorial Sloan Kettering experience. J Cancer Res Clin Oncol 2001;127(suppl 2):R20-R26.
8. Holmberg LA, Sandmaier BM. Vaccination with Theratope (STn-KLH) as treatment for breast cancer. Expert Rev Vaccines 2004;3:655-663.
9. Miles DW, Happerfield LC, Smith P et al. Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancer. Br J Cancer 1994;70:1272-1275.
10. Miles DW, Linehan J, Smith P et al. Expression of sialyl-Tn in gastric cancer: Correlation with known prognostic factors. Br J Cancer 1995;71: 1074-1076.
11. Kinney AY, Sahin A, Vernon SW et al. The prognostic significance of sialyl- Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. Cancer 1997;80:2240-2249.
12. Kolbayashi H, Terao T, Kawashima Y. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J Clin Oncol 1992;10:95-101.
13. Longenecker BM, Reddish M, Koganty R et al. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant. Ann N Y Acad Sci 1993; 690:276-291.
14. Itzkowitz SH, Yuan M, Montgomery CK et al. Expression of Tn, sialosyl- Tn, and T antigens in human colon cancer. Cancer Res 1989;49:197-204.
15. MacLean GD, Reddish M, Koganty RR et al. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol Immunother 1993;36:215-222.
16. MacLean GD, Reddish MA, Koganty RR et al. Antibodies against mucinassociated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother Emphasis Tumor Immunol 1996;19: 59-68.
17. Miles DW, Towlson KE, Graham R et al. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer 1996;74:1292-1296.
18. Bass KK, Mastrangelo MJ. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother 1998;47:1-12.
19. MacLean GD, Miles DW, Rubens RD et al. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol 1996;19:309-316.
20. Holmberg LA, Sandmaier BM. Theratope_ vaccine (STn-KLH). Expert Opin Biol Ther 2001;1:881-891.
21. Reddish MA, MacLean GD, Poppema S et al. Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69_lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother 1996;42:303-309.
22. ® (STn-KLH) with Detox™-B stable emulsion for treatment of MBC following first-line chemotherapy. Presented at the 1999 Annual Meeting of the American Society of Clinical Oncology, Atlanta, Georgia, May 15-18, 1999.
23. Miles D, Papazisis K. Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer. Clin Breast Cancer 2003;3(suppl 4):S134-S138.
24. Fayers P, Aaronson N, Bjordal K et al. EORTC QLQ-C30 Scoring Manual. Brussels, Belgium: EORTC Study Group on Quality of Life, 1995.
25. Zhang S, Walberg LA, Ogata S et al. Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen. Cancer Res 1995;55:3364-3368.
26. Lan KK, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:654-663.
27. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556.
28. Foy TM, Fanger GR, Hand S et al. Designing HER2 vaccines. Semin Oncol 2002;29(suppl 11):53-61.
29. Cristofanilli M, Hortobagyi GN. New horizons in treating metastatic disease. Clin Breast Cancer 2001;1:276-287.
30. Reilly RT, Emens LA, Jaffee EM. Humoral and cellular immune responses: Independent forces or collaborators in the fight against cancer? Curr Opin Investing Drugs 2001;2:133-135.
31. Pitroda SP, Khodarev NN, Beckett MA et al. MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc Natl Acad Sci U S A 2009;106:5837-5841.
32. Wei X, Xu H, Kufe D. MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell 2006;21:295-305.
33. Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: Depletion of CD4+2H4+suppressor inducer T-cell. Cancer Res 1988;48:1671-1675.
34. Berd D, Mastrangelo MJ, Engstrom PF et al. Augmentation of the human immune response by cyclophosphamide. Cancer Res 1982;42:4862-4866.
35. Sànchez-Muñoz A, Pérez-Ruiz E, Ribelles N et al. Maintenance treatment in metastatic breast cancer. Expert Rev Anticancer Ther 2008; 8:1907-1912.